With the issue of data exclusivity for novel biologics re-emerging in the news, I’d like to present two arguments that […]
Biologic data exclusivity: The arguments for and against it Read Post »
With two life science IPOs earlier this month, and seemingly fewer stories of biotechnology firm liquidations, it seems that the
Biotechnology Industry Organization CEO Jim Greenwood appeared on CNBC’s SquawkBox defending the case for data exclusivity protection for novel biologic
Jim Greenwood on Data Exclusivity and Healthcare Innovation Read Post »